Objective: To investigate the effects of cardiotrophin-1 (CT-1) on differentiation of induced rat bone marrow mesenchymal stem cells (BMMSCs) in vitro with 5-azacytidine (5-aza) for the purpose of elucidation of the cellular biological mechanisms.
Methods: BMMSCs isolated from femur of rats were divided into four groups: untreated group as control (group A); 0.1 nmol/L CT-1 added to medium (Group B); induced with 10 micromol/L 5-aza only (Group C); induced with 10 micromol/L 5-aza combined with 0.1 nmol/L CT-1 added to medium (Group D). After 4 weeks of induced culturing, the differentiation of induced myocyte like cells were estimated, levels of cardiac troponin-T (cTnT) by immunohistochemical staining and ultrastructure of induce-cultured BMMSCs were determined and mRNA expression of alpha-actin, beta-myosin heavy chain (beta-MHC), Nkx2.5, GATA4 were analyzed by real time polymerase chain reaction (RT-PCR).
Results: After 4 weeks of induced culturing, morphological characteristics of myocyte like cells with the expression of cTnT were observed in group C and D cells. Higher level expression of GATA4, Nkx2.5, alpha- actin and beta-MHC mRNA in group D was observed by comparing with those of group C and the differentiated BMMSCs with formations of myofilaments distinctly were also existed in 5-aza combined with CT-1 treatment group.
Conclusion: This study suggests that induced culturing of BMMSCs in the presence of 5-aza combined with CT-1 can enhance cardiomyocytic characteristics. CT-1 upregulates the expression of GATA4, Nkx2.5, alpha-actin and beta-MHC mRNA, and rapidly promotes the differentiation and maturation of cardiomyocyte-like cells differentiated from BMMSCs induced with 5-aza.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Whole-Genome Methylation Sequencing Analysis and Functional Verification of LIM-Homeobox Family Genes in Cervical Cancer.
Int J Gen Med
January 2025
Department of Radiation Oncology, Peking University Cancer Hospital (Inner Mongolia Campus) & Affiliated Cancer Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, 010020, People's Republic of China.
Background: Gene methylation in cells is an important factor in tumorigenesis, and radiotherapy can change DNA methylation in cells. In this study, complete genome methylation sequencing (BS-Seq) technology was used to analyze the genome-wide methylation of patients with cervical cancer before and after radiotherapy.
Methods: Three pairs of cervical squamous cell carcinoma samples were collected from patients before and after radiotherapy in July 2020.
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.
J Exp Clin Cancer Res
January 2025
Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Background: Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy. While this is an important treatment option, many patients fail to achieve complete remission and of those that do, majority relapse. Leukemia stem cells (LSCs) are believed to be responsible for AML relapse and can be targeted through oxidative phosphorylation reduction.
View Article and Find Full Text PDFSingle-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.
Ther Adv Hematol
January 2025
Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157, 5th West Road, Xi'an, Shaanxi 710004, China.
Background: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML).
Objectives: To retrospectively analyze the efficacy and safety of VEN combined with azacitidine (AZA) in young adult patients with newly diagnosed (ND) AML.
The Simultaneous Treatment of PC-3 Cells with the DNA-Demethylating Agent Decitabine and S-Adenosylmethionine Leads to Synergistic Anticancer Effects.
Genes (Basel)
December 2024
Department of Bioinformatics, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Epigenetic dysregulation is a common feature of cancer. Promoter demethylation of tumor-promoting genes and global DNA hypomethylation may trigger tumor progression. Epigenetic changes are unstable; thus, research has focused on detecting remedies that target epigenetic regulators.
View Article and Find Full Text PDFAt-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.
Cancers (Basel)
December 2024
Department of Hematology, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial management a challenging phase. This difficulty in our center led to the establishment of an At-Home (AH) program for ramp-up and follow-up patients during the VenAza combination induction phase focused on therapy administration, patient and caregiver education, and management of adverse events (AEs). A total of 70 patients with newly diagnosed acute myeloid leukemia (ND-AML) or relapsed/refractory AML (R/R AML) were treated with VenAza from March 2019 to May 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!